{"id":"methylphenidate-hydrochloride-controlled-release-capsules","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Insomnia"},{"rate":"10-20","effect":"Decreased appetite"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Nervousness or anxiety"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1722","moleculeType":"Small molecule","molecularWeight":"269.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate inhibits the reuptake of dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced neurotransmitter activity improves attention, focus, and impulse control. The controlled-release formulation provides sustained drug delivery over an extended period, allowing for once-daily dosing.","oneSentence":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the presynaptic neuron.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:46.400Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT03785223","phase":"PHASE4","title":"A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity","status":"COMPLETED","sponsor":"McMaster University","startDate":"2019-04-20","conditions":"Attention Deficit Hyperactivity Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder","enrollment":60},{"nctId":"NCT04507204","phase":"PHASE4","title":"Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"TERMINATED","sponsor":"Purdue Pharma LP","startDate":"2020-07-30","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":267},{"nctId":"NCT03811847","phase":"PHASE4","title":"A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-11-01","conditions":"Alzheimer Dementia","enrollment":11},{"nctId":"NCT02683265","phase":"PHASE4","title":"A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-04-25","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":158},{"nctId":"NCT04152629","phase":"PHASE4","title":"Real World Evidence of the Efficacy and Safety of FOQUEST","status":"COMPLETED","sponsor":"Purdue Pharma, Canada","startDate":"2019-09-19","conditions":"Attention Deficit-Hyperactivity Disorder","enrollment":257},{"nctId":"NCT02700685","phase":"PHASE3","title":"Effect of Pycnogenol® on ADHD","status":"COMPLETED","sponsor":"Nina Hermans","startDate":"2017-09-01","conditions":"ADHD","enrollment":88},{"nctId":"NCT01399827","phase":"PHASE2","title":"Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-02","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)","enrollment":2},{"nctId":"NCT00516269","phase":"PHASE3","title":"Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-08","conditions":"Breast Cancer, Fatigue, Gastrointestinal Cancer","enrollment":42},{"nctId":"NCT00302458","phase":"PHASE4","title":"A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-01","conditions":"Healthy","enrollment":44},{"nctId":"NCT01879202","phase":"PHASE2","title":"Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2012-12","conditions":"Multiple Sclerosis, Fatigue","enrollment":96},{"nctId":"NCT01338818","phase":"PHASE3","title":"Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":299},{"nctId":"NCT01259492","phase":"PHASE3","title":"Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":725},{"nctId":"NCT01377662","phase":"PHASE2","title":"PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)","status":"COMPLETED","sponsor":"Tong Lee","startDate":"2011-08","conditions":"Methamphetamine Dependence, Cocaine Dependence","enrollment":30},{"nctId":"NCT00922636","phase":"PHASE2, PHASE3","title":"A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":340},{"nctId":"NCT01348607","phase":"PHASE2","title":"Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy","status":"TERMINATED","sponsor":"University of South Florida","startDate":"2010-07","conditions":"Central Nervous System Tumor, Pediatric, Fatigue, Specific Disorders of Sleep","enrollment":1},{"nctId":"NCT00593112","phase":"PHASE4","title":"Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-11","conditions":"ADHD","enrollment":39},{"nctId":"NCT00776009","phase":"PHASE4","title":"Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":165},{"nctId":"NCT00619840","phase":"PHASE3","title":"Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD","status":"COMPLETED","sponsor":"Medice Arzneimittel Pütter GmbH & Co KG","startDate":"2004-11","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":363}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Foquest"],"phase":"marketed","status":"active","brandName":"Methylphenidate Hydrochloride Controlled-Release Capsules","genericName":"Methylphenidate Hydrochloride Controlled-Release Capsules","companyName":"McMaster University","companyId":"mcmaster-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the presynaptic neuron. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}